The Maryland Task Force on Responsible Use of Natural Psychedelic Substances released a final report recommending a multi-phase framework for legal, therapeutic access to natural psychedelics, starting with psilocybin. The plan involves phased implementation of medical/therapeutic use, supervised adult use, deprioritization measures, and eventually commercial sales, with the goal of ensuring safe, broad, and equitable access. The task force does not support delaying state action pending future FDA approval and emphasizes an "ensemble model" approach that balances public health, patient safety, equity, and scientific integrity, positioning Maryland as a potential national leader in psychedelic policy reform. The report also estimates potential client numbers and consumer spending if psilocybin is legalized.

Maryland Task Force Recommends Phased Psychedelics Legalization Beginning with Psilocybin

Nov 6, 2025

Source:

Kyle Jaeger

Marijuana Moment

Maryland is taking a bold step beyond cannabis as its psychedelics task force just dropped a final report recommending a phased rollout for legal access to natural plant medicines. This "ensemble model" prioritizes psilocybin first, proposing a three-step journey that moves from establishing safety boards to medical use and, eventually, a regulated commercial market. Crucially, the group isn't waiting for the FDA to catch up, suggesting that Maryland should lead the way in restorative justice and personal cultivation rights.

This is huge for the community because it treats natural substances with the same logic we've fought for in cannabis: focus on public health and equity rather than outdated criminalization. By building a framework for supervised use and eventually retail sales, Maryland is creating a blueprint for safe, accessible plant medicine that bypasses the "gray market" chaos seen in other states. For everyday enthusiasts, this means the future of wellness in the DMV might soon include more than just a great jar of flower; it could mean a fully legal, professional pathway to therapeutic psychedelics.